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Abstract
Aim: Intrauterine growth restriction (IUGR) is an inde-
pendent risk factor for the development of cardiovascular 
diseases later in life. The mechanisms whereby slowed 
intrauterine growth confers vascular risk are not clearly 
established. In general, a disturbed cholesterol efflux has 
been linked to atherosclerosis. The capacity of serum to 
accept cholesterol has been repeatedly evaluated in clini-
cal studies by the use of macrophage-based cholesterol 
efflux assays and, if disturbed, precedes atherosclerotic 
diseases years before the clinical diagnosis. We now 
hypothesized that circulating cholesterol acceptors in 
IUGR sera specifically interfere with cholesterol transport 
mechanisms leading to diminished cholesterol efflux.
Methods: RAW264.7 cells were used to determine efflux 
of [3H]-cholesterol in response to [umbilical cord serum 
(IUGR), n = 20; controls (CTRL), n = 20].
Results: Cholesterol efflux was lower in IUGR as com-
pared to controls [controls: mean 7.7% fractional [3H]-
cholesterol efflux, standard deviation (SD) = 0.98; IUGR: 
mean 6.3%, SD = 0.79; P < 0.0001]. Values strongly corre-
lated to HDL ( ρ = 0.655, P < 0.0001) and apoE ( ρ = 0.510, 
P = 0.0008), and mildly to apoA1 ( ρ = 0.3926, P = 0.0122) 
concentrations.
Conclusions: Reduced cholesterol efflux in IUGR could 
account for the enhanced risk of developing cardiovascu-
lar diseases later in life.
Keywords: Atherosclerosis; cholesterol; efflux; fetal pro-
gramming; IUGR; lipids.
Introduction
Intrauterine growth restriction (IUGR) refers to a condi-
tion in which the fetus does not reach its genetically given 
growth potential. It is an interdisciplinary challenge for 
obstetricians and pediatricians affecting approximately 
3%–8% of all pregnancies and contributing majorly to 
fetal and neonatal morbidity and mortality. Early (preterm) 
delivery is the only treatment option to prevent intrauter-
ine death and fetal asphyxia [1]. Apart from its immediate 
clinical relevance, IUGR has an enormous socioeconomic 
impact [2] and is generally considered as an independent 
risk factor for the development of cardiovascular diseases 
later in life [3, 4].
The pathomechanisms by which the intrauterine 
condition increases the atherosclerotic burden is still a 
matter of debate [5, 6]. We and others recently showed 
that cord blood lipid profile of IUGR fetuses favors a high-
density lipoprotein (HDL) depleted phenotype leading 
to an increase in low-density lipoprotein (LDL)/HDL 
ratio. This clearly distinguishes IUGR from constitutional 
small for gestational age and adequate for age-weighted 
preterm and term born fetuses [7, 8]. In general, a low level 
of HDL-cholesterol is a major independent risk factor for 
atherosclerotic cardiovascular disease in adults [9]. The 
antiatherogenic properties of HDL are mainly related to its 
role in reverse cholesterol transport from the periphery to 
the liver and its rate-limiting step, the cholesterol efflux 
from the cells into the circulation, which protects the cells 
from cholesterol overload. On the cellular level, choles-
terol efflux from macrophages or endothelial cells involves 
a stepwise cascade with cholesterol being effluxed to its 
circulating acceptors in the blood, namely, apolipoprotein 
A1 (apoA1) and HDL, by the ATP binding cassette trans-
porters ABCA1 and ABCG1, and the scavenger receptor B1 
(SR-B1) pathways [10, 11]. The capacity of blood to accept 
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cholesterol from the cells depends on the concentration 
and functionality of the circulating cholesterol acceptors 
and can be measured ex vivo using cell-based cholesterol 
efflux assays. Clinical studies revealed inverse correlations 
between cholesterol acceptor capacity and prevalent coro-
nary artery disease [12–14]. Moreover, the HDL-mediated 
acceptor capacity has been demonstrated to be a more 
powerful determinant of future incident cardiovascular 
outcome over a 9-year observation period than classic risk 
factors or HDL concentration alone [15].
The aim of the present investigation was to character-
ize cholesterol acceptor capacity of cord blood from IUGR 
and a control (CTRL) group by the use of a well-estab-
lished mouse-macrophage-based cholesterol efflux assay 
[10, 16, 17]. We hypothesized that cholesterol homeostasis 
in IUGR fetuses is disturbed by reduced acceptor capac-
ity, taking into account the unique acceptor composition 
with apoE beside HDL and apoA1 playing a functional role 
in fetal cholesterol transport [11, 17]. We speculate that a 
lower fetal cholesterol acceptor capacity during a critical 
fetal developmental phase is a determinant of atheroscle-
rotic diseases later in live.
Materials and methods
Study cohort – umbilical vein serum samples
Venous cord blood was sampled at a single university hospital 
between March 2008 and March 2012. The study was approved by the 
Institutional Ethics Committee (EK 119/08 and 154/11). The authors 
complied with the World Medical Association Declaration of Hel-
sinki regarding ethical conduct of research involving human sub-
jects. Written informed consent was obtained from all participating 
 parents.
IUGR was diagnosed antenatally as recently described [8] and 
defined in accordance with the guidelines of the American College 
of Obstetricians and Gynecologists [1] as an estimated fetal weight 
< 10th percentile in addition to at least one of the following criteria: (1) 
deceleration of fetal growth rate > 40th percentiles, (2) elevated resist-
ance index in umbilical artery Doppler sonography above the 95th 
percentile, (3) head-to-abdominal circumference ratio > 95th percen-
tile, or (4) amniotic fluid index < 6 cm. Five of the IUGR cases addi-
tionally were complicated by preeclampsia as defined by the ISSHP 
criteria [18].
A total of 299 patients giving birth at the university hospital 
were enrolled during the study period. Of those, we identified 20 
IUGR cases with sufficient serum volume to be further used for the 
planned analyses. Sixteen of the IUGR fetuses needed mandatory 
preterm delivery before 37 weeks of gestation (WOG). The IUGR cases 
were matched with CTRL as closely as possible for maternal age, 
gestational age, fetal gender, betamethasone administration, mater-
nal smoking habits, and maternal body mass index (BMI). Neonatal 
weight in the CTRL group was within the 10th and 90th percentiles. 
Fourteen of the 20 CTRL fetuses were born preterm before 37 WOG for 
various reasons (premature rupture of the membrane, spontaneous 
onset of labor, and vaginal bleeding). None of the CTRL mothers suf-
fered from hypertension or preeclampsia.
Exclusion criteria were defined as multiple gestation, fetal 
anomalies, abnormal fetal karyotype, patients with clinical or bio-
chemical signs of infection, positive toxoplasmosis, rubella, cyto-
megalovirus, herpes simplex, and HIV (TORCH) screening results, 
maternal diabetes mellitus/gestational diabetes or other severe 
maternal metabolic disorders, and the patient's withdrawal from the 
study. All neonates were delivered by caesarean section. Sample stor-
age times and conditions were equal for all groups.
Blood sampling, serum generation, and storage 
of  aliquots
Blood samples (up to 4.9  mL each) were taken postnatally from 
a double-clamped umbilical cord vein using Monovette syringes 
(Serum 4.9  mL Monovette; Sarstedt, Nümbrecht, Germany). After 
incubation at room temperature for 15–30 min, samples were centri-
fuged at 2000 g for 15 min. Serum was aliquoted and stored at − 80°C.
Basic serum lipid profiling
Analysis of serum triglycerides (TG), TC, LDL- and HDL-cholesterol, 
and total protein (TP) was performed by colorimetric enzymatic 
methods using an automated photometric measuring unit (Roche/
Hitachi Modular P800; Roche Diagnostics, Basel, Switzerland) as 
described [8].
Enzyme-linked immunosorbent assay (ELISA)
ApoA1 and apoE concentrations were determined by ELISA (Mabtech, 
Nacka Strand, Sweden) in duplicates according to the manufactur-
er's protocol [17].
Cholesterol efflux assays
Cholesterol efflux analysis was determined as described [16, 17] with 
RAW264.7 (ATCC, USA) using the various sera as acceptor. Cells were 
labeled for 48 h with 0.2 µCi/mL [3H]-cholesterol (Anawa, Switzer-
land), washed six times with phosphate-buffered saline (PBS, pH 
7.4), and further equilibrated for 18 h in OptiMem. Cells were washed 
with PBS and further incubated in the presence or absence of 5% 
serum 120 min. Radioactivity was measured in medium and cells. 
Fractional [3H]-cholesterol efflux was calculated as the percentage of 
labeled cholesterol released to the medium divided by the amount of 
total labeled cholesterol in the medium and cells. A standard serum 
pool was prepared from three healthy (nonpregnant) volunteers, ali-
quoted and frozen at − 80°C, and used with each assay as a reference. 
Intra- and interassay variance was less than 10%.
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Statistics
nQuery Advisor 7.0 [Janet D. Elashoff (2007), CA, USA] was used for 
sample size calculation. The minimal required sample size was esti-
mated on the basis of cord blood HDL-cholesterol concentrations 
published previously [8]. Choosing a power of 80% and a level of 
significance less than 0.05, at least five patients had to be included 
in each group.
Data analysis was conducted using the statistical packages 
Prism Version 6.0e Software (GraphPad Software Inc., CA, USA). 
Clinical data are presented as means ± standard deviations (SD) if 
metric. Categorical data are presented as frequencies and percent-
ages. Laboratory variables are expressed as means ± SD. A two-
tailed Mann-Whitney test was conducted for comparison of metric 
variables. Fisher's exact test was used for categorical data. Correla-
tions were analyzed by Spearman's correlation coefficient. Values of 
P < 0.05 were regarded as significant.
Exploratory confounder analyses were done by linear regres-
sion. In case of association, the respective variable was further tested 
by subgroup analysis.
Results
Clinical characteristics of study cohort
Maternal and neonatal characteristics are summarized 
in Table 1. Maternal age, smoking habits, gestational age 
at delivery, days after betamethasone administration, 
and fetal gender were kept well adjusted. Seven patients 
in the IUGR group and five patients in the CTRL group 
were overweight to obese per definition of the World 
Health Organization with a prepregnancy BMI > 25 kg/m2. 
Five (25%) of the 20  mothers of the IUGR group were 
hypertensive.
Serum biochemistry
Lipid and apolipoprotein profile
Lipid and apolipoprotein profile is displayed in Table 2. 
Mean TC concentration was 30.8% lower in IUGR as com-
pared with CTRL (P < 0.0001). Mean HDL concentration 
was 59.4% lower (P < 0.0001), and mean LDL concentration 
Table 1: Clinical characteristics of the study cohort.
CTRL IUGR P-value
Mean or n SD or % Mean or n SD or %
Total number of neonates n 20 20
Maternal age (years) mean (SD) 32.6 6.0 29.5 7.2 0.2036
Maternal prepregnancy BMI (kg/m2) mean (SD) 22.6 3.5 26.1 6.6 0.1591
Maternal parity (primiparity) n (%) 6 30 12 60 0.1110
Maternal hypertension > 140/90 mm Hg n (%) 0 0 5 25 0.0471
Maternal prepregnancy smoking status (smoker) n (%) 10 50 7 35 0.5230
Maternal smoking status during pregnancy (smoker) n (%) 4 20 5 25 1.0000
Gestational age at birth (weeks) mean (SD) 34.2 3.4 34.2 3.2 0.9947
Neonatal gender (female) n (%) 11 55 55 1.0000
Neonatal weight at birth (g) mean (SD) 2349 788 1540 533 0.0011
Neonatal birth weight percentile mean (SD) 45 15 4 3 < 0.0001
Neonatal umbilical artery pH mean (SD) 7.343 0.035 7.301 0.038 0.0006
Neonatal Apgar score mean (SD) 9.5 0.7 9.3 0.9 0.6063
Betamethasone application during pregnancy n (%) 8 40 10 50 0.7512
Betamethasone exposure (days prior to delivery) mean (SD) 14.5 14.7 12.3 10.6 1.0000
Storage time at − 80°C (years) mean (SD) 2.39 0.77 2.03 1.04 0.3044
P-value < 0.05 (bold) are considered as significant.
Table 2: Lipid, lipoprotein, and apolipoprotein concentrations.
CTRL IUGR P-value
Mean SD Mean SD
TC (mmol/L) 1.86 0.45 1.29 0.29 < 0.0001
LDL-C (mmol/L) 0.70 0.33 0.53 0.27 0.0622
HDL-C (mmol/L) 0.92 0.19 0.37 0.11 < 0.0001
LDL-C/HDL-C 0.78 0.39 1.44 0.67 0.0002
TG (mmol/L) 0.19 0.12 0.55 0.42 < 0.0001
ApoA1 (µmol/L) 28.39 7.40 23.62 6.65 0.0157
ApoE (µmol/L) 2.96 2.41 1.57 1.34 0.0002
TP (g/L) 47.90 8.57 48.25 8.52 0.8670
P-value < 0.05 (bold) are considered as significant.
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was lower by 24.0% (P = 0.0622) in the IUGR group as com-
pared with CTRL. Consequently, the mean LDL/HDL ratio 
was 83.3% higher in the IUGR group as compared with 
CTRL (P = 0.0002).
Although mean apoA1 concentration was slightly 
(16.8%) lower in the IUGR than in the CTRL group 
(P = 0.0157), apoE levels were reduced by 46.8% in IUGR 
as compared with CTRL fetuses (P = 0.0002). Correlation 
analyses revealed a moderate correlation of apoA1 concen-
trations to TC ( ρ = 0.480, P = 0.0017) and HDL ( ρ = 0.344, 
P = 0.03) values. ApoE concentrations were highly corre-
lated to HDL ( ρ = 0.638, P < 0.0001) and mildly to moder-
ately correlated to TC and LDL, respectively (TC: ρ = 0.466, 
P < 0.0025; LDL: ρ = 0.358, P < 0.0235).
Cholesterol efflux assays
Fractional cholesterol efflux was 18.4% lower when using 
serum of the IUGR group (mean = 6.25%, SD = 0.79; units: 
% fractional [3H]-cholesterol efflux) in comparison with 
the CTRL group (mean = 7.66%, SD = 0.98, P < 0.0001) 
(Figure  1). Overall fractional cholesterol efflux from 
RAW264.7 cells correlated moderately to highly to con-
centrations of the cholesterol acceptors HDL ( ρ = 0.655, 
P < 0.0001) and apoE ( ρ = 0.510, P = 0.0008), and mildly to 
apoA1 ( ρ = 0.3926, P = 0.0122).
Confounder analysis
Possible confounding factors were considered based 
on previous reports on cord blood lipid concentrations. 
These were gestational age at delivery and birth weight, 
neonatal weight percentile, gender of the neonate, fetal 
distress during labor as assessed by postpartum pH and 
a 5-min Apgar score, maternal smoking status, and beta-
methasone application to the mother [8, 17, 19–23]. We 
also analyzed the influence of blood pressure, maternal 
age, BMI, and parity. R2 values of the linear regression 
analysis are presented in Table 3. Associations were 
found for BMI, parity, umbilical artery pH, and beta-
methasone application, and for neonatal birth weight 
and birth weight percentiles. As part of the definition of 
IUGR, the latter is not considered as confounders. The 
differences between IUGR and CTRL persisted when sub-
grouping lean (BMI < 25 kg/m2) and overweight (BMI  ≥  25 
kg/m2) patients [lean: CTRL 7.88% (SD = 0.90) vs. IUGR 
6.46% (SD = 0.85), P = 0.0004; overweight: CTRL 6.98% 
(SD = 1.00) vs. IUGR 5.85 (SD = 0.48), P = 0.048] and pri-
miparous and multi parous mothers [primiparity: CTRL 
7.34% (SD = 0.97) vs. IUGR 6.12% (SD = 0.87), P = 0.0320; 
multipara: CTRL 7.80% (SD = 0.99) vs. IUGR 6.46% 
(SD = 0.63), P = 0.0029]. Likewise, subgrouping patients 
by median of pH [higher than median pH: CTRL 7.84% 
(SD = 1.04) vs. IUGR 6.38% (0.94), P = 0.0052; lower 
pH: CTRL 7.44% (SD = 0.91) vs. IUGR 6.09% (SD = 0.57), 
P = 0.004] or by betamethasone application [betametha-
sone: CTRL 7.24% (SD = 0.79) vs. IUGR 5.96% (SD = 0.40), 
P = 0.0021; no betamethasone: CTRL 7.94% (SD = 1.03) vs. 150
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Figure 1: Estimating cholesterol acceptor capacity by cell-based 
[3H]-cholesterol efflux assay.
Cells were incubated with 5% serum for 2 h, and the percentage 
of cholesterol removal from the cells to the medium (fractional 
 [3H]-cholesterol efflux) was calculated. IUGR (gray, n = 20) vs. CTRL 
(white, n = 20). Displayed are mean and SD values in % of CTRL. 
Statistical analysis was done by Mann-Whitney test. Significance is 
indicated by P-value.
Table 3: Confounder analysis.
R2 P-value
Maternal age 0.059 0.131
Maternal prepregnancy BMI 0.140 0.018
Maternal primiparity 0.125 0.026
Maternal systolic blood pressure 0.077 0.084
Maternal diastolic blood pressure 0.041 0.211
Maternal prepregnancy smoking status 0.013 0.487
Maternal smoking status during pregnancy 0.010 0.531
Gestational age (weeks) at birth 0.032 0.267
Fetal gender 0.006 0.644
Fetal weight at birth 0.194 0.005
Fetal birth weight percentile 0.297 0.000
Fetal umbilical artery pH 0.199 0.004
Fetal Apgar score 0.043 0.200
Betamethasone application 0.120 0.029
Storage time at − 80°C 0.063 0.118
Higher R2 values with a P-value < 0.05 (bold) are considered as a 
potential confounder.
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IUGR 6.54% (SD = 0.98), P = 0.0071] persistently showed 
significant differences between the IUGR and CTRL 
group.
Discussion
In the present investigation, we have characterized the func-
tional relevance of a low HDL concentration in the IUGR 
fetus with respect to the role of HDL and associated apolipo-
proteins in triggering cholesterol efflux. Uniquely, sera from 
IUGR fetuses were less likely to accept cholesterol. Both HDL 
and apoE concentrations are associated with cholesterol 
efflux values, but we observed only mild associations with 
apoA1. In a recent prospective study, the serum cholesterol 
acceptor capacity has been demonstrated to be a more pow-
erful determinant of atherosclerosis than HDL concentra-
tion alone and an independent predictor of cardiovascular 
events over a 9-year observation period [15]. Yet the differ-
ence between IUGR and CTRL in the present study was twice 
as high as the effect recently reported by Khera et al. [12] 
who evaluated serum cholesterol acceptor capacity in adult 
patients with incident coronary artery disease.
In terms of atherosclerosis in human adults, the pro-
tective effect of HDL by promoting reverse cholesterol 
transport and its first and rate-limiting step, the efflux of 
cholesterol from cells of the periphery into an acceptor 
in the circulation, is evident [12, 15]. Studies in mice have 
shown that macrophage-specific cholesterol efflux and 
reverse cholesterol transport are inversely correlated with 
atherosclerotic lesion size [24]. Of note,  HDL-mediated 
cholesterol efflux not only reduces atherosclerosis by 
preventing cells from cholesterol overload. In endothe-
lial cells, HDL-promoted cholesterol efflux also activates 
endothelial nitric oxide synthase and interferes with the 
vascular endothelial growth factor receptor 2, thus pro-
moting endothelial repair and angiogenesis [25, 26]. Defec-
tive cholesterol efflux has also been linked to increased 
platelet reactivity and proliferation in vitro [27]. Thus, HDL-
mediated cholesterol efflux may have multiple atheropro-
tective functions. Regrettably, therapies targeting HDL and 
HDL composition to prevent cardiovascular events have 
been disappointing to date [28]. Therefore, pharmacologic 
interventions in adults mainly aim at lowering total and 
LDL cholesterol concentrations and at restoring LDL/HDL 
balance using statins and/or PCSK9 inhibitors [29].
Several studies suggest that atherogenesis in the fetus 
and in childhood is similar to those observed in adults 
involving LDL oxidation and the formation of fatty streaks 
[30]. In post mortem analyses of children aged 1–13 years, 
the number of aortic atherosclerotic lesions is inversely 
correlated to birth weight [31]. Clinically, in children born 
with IUGR, atherosclerosis is evident by ultrasound-based 
measurement of aortic intima-media thickening as early 
as postnatally and intrauterine [32–34]. Zanardo et al. [33] 
followed 25 IUGR children and 25 CTRL up to the age of 
18  months. They found that persisting early childhood 
aortic thickening was associated with higher blood pres-
sure values, suggesting a causal alteration of the vascular 
structure and function in IUGR-children.
Paradoxically to its future risk of atherosclerosis, and 
by contrast to the atherogenic profile in adults, beside 
lower HDL levels, lower cord blood total cholesterol con-
centrations in IUGR fetuses compared with CTRL fetuses 
were observed [7, 8]. This may be explained by several 
profound differences between the fetal and the adult lipid 
composition and metabolism. HDL is the most dominant 
lipoprotein in the fetus, and this results into a much lower 
LDL/HDL ratio than in adults [8]. Moreover, compared with 
other lipid and lipoprotein fractions, fetal HDL concentra-
tion and function is a remarkable constant throughout 
the second half of gestation, supporting a fundamental 
and highly conserved role for HDL in the maintenance 
of fetal cholesterol homeostasis [17]. Notably, apoE com-
pared with other apolipoproteins is highly concentrated in 
the fetal circulation as levels are as high as in adults [35]. 
Moreover, fetal HDL-particle has been demonstrated to 
contain remarkably high amounts of apoE. Enrichment of 
HDL3 with apoE enhances cholesterol efflux as compared 
with apoE-free HDL3 particles [11]. These findings are sup-
ported by the present study because apoE levels in addi-
tion to HDL highly determined cholesterol efflux values. 
The source of cord blood apoE is still a matter of debate. 
Term placental trophoblasts are principally enabled to 
synthesize and secrete apoE. However, placental perfu-
sion experiments revealed that more than 80% of the apoE 
synthesized in the placenta is secreted toward the mater-
nal circulation [36]. A more likely source of fetal apoE may 
therefore be the fetal liver or the mother, possibly via pla-
cental uptake of maternal apoE-rich very low-density lipo-
protein particles [37]. This interesting hypothesis merits 
further investigations and current studies are underway to 
address this question.
Taken together, our data are in concert with the 
present literature on subclinical atherosclerosis in IUGR 
neonates. We provide evidence for a well-established 
mechanistic link promoting premature atherosclerosis 
being applicable in the light of intrauterine development 
despite of a low-cholesterol availability.
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